Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Baxter
Boehringer Ingelheim
Mallinckrodt
Dow

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Litigation Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

See Plans and Pricing

« Back to Dashboard

Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Docket   Start Trial Date Filed 2016-01-15
Court District Court, N.D. Illinois Date Terminated 2018-12-17
Cause 35:271 Patent Infringement Assigned To Rebecca R. Pallmeyer
Jury Demand None Referred To
Parties FRESENIUS KABI USA, LLC; HOSPIRA, INC.
Patents 6,716,867; 8,242,158; 8,338,470; 8,455,527; 8,648,106; 9,320,712; 9,616,049
Attorneys Aaron A. Barlow; Ahmed M. T. Riaz; Bradford P. Lyerla; Chad J. Ray; Emily Michelle Pena; Gina M Bassi; Imron T Aly; Joel M Wallace; Kevin Michael Nelson; Ren-How H. Harn; Sara Tonnies Horton; Tara Lauren Kurtis; Yusuf Esat
Firms Chad J. Ray; Jenner & Block; Jenner & Block, LLP; Schiff Hardin LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Hospira, Inc. v. Fresenius Kabi USA, LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 infringement of U.S. Patent Nos. 8,242,158 (the “‘158 patent”) (Ex. A); 8,338,470 (the “‘470 patent”) (Ex. B); … COUNT I FOR INFRINGEMENT OF PATENT NO. 8,242,158 22. Paragraphs 1 through… claims of the ‘158 patent, the ‘470 patent, the ‘527 patent, and the ‘106 patent are invalid and/or … “‘527 patent”) (Ex. C); and 8,648,106 (the “‘106 patent”) (Ex. D) (collectively, the “Patents-in-suit… THE PATENTS-IN-SUIT 9. The ‘158 patent, entitled “Dexmedetomidine External link to document
0000-00-00 176 Order on Motion for Leave to File obtained four patents covering a new product made from dexmedetomidine: U.S. Patent Nos. 8,242,158 (the “’158…’158 Patent”), 8,338,470 (the “’470 Patent”), 8,455,527 (the “’527 Patent”), and 8,648,106 (the “’106…product—U.S. Patent No. 9,616,049 (the “’049 Patent”)—and filed a second complaint of patent infringement…obtained a patent that disclosed and claimed the compound: U.S. Patent No. 4,910,214 (the “’214 Patent”), JTX…named co- inventors of the patents-in-suit. (See ’106 Patent, JTX 1; ’049 Patent, JTX 2.) Dr. Roychowdhury External link to document
2017-11-27 69 . No. 6,716,867.” (‘527 Patent, JA-34, col. 10 ll. 33–35.) The patent referenced, No. 6,716,867, is the…The claim terms in the '158 Patent, '470 Patent, '527 Patent, and '106 Patent are construed as stated in…The claim terms in the ‘158 Patent, ‘470 Patent, ‘527 Patent, and ‘106 Patent are construed as follows:…8,242,158 (the “ ‘158 Patent”), 8,338,470 (the “ ‘470 Patent”), 8,455,527 (the “ ‘527 Patent”), and 8,648,106…106 Patent, JA-43.) The Patent Office issued the patents between August 14, 2012, and February 11, 2014 External link to document
0000-00-00 72 infringing U.S. Patent Nos. 8,242,158 (the“’158 patent”); 8,338,470 (the “’470 patent”); 8,455,527 (the… U.S. Patent No. 9,616,049 (“the ’049 patent”). Like the patents in Hospira I, the ’049 patent claims…the “’527 patent”); and 8,648,106 (the “’106 patent”) (collectively, “Hospira I Patents”). The ’158, …asserting that the ’049 patent and U.S. Patent No. 9,320,712 (“the ’712 patent”) were invalid and not …family as the ’049 patent and the Hospira I patents. The ’712 patent also shares the same specification External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
AstraZeneca
Colorcon
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.